Published in Bone Marrow Transplant on April 22, 2013
Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA (2014) 2.01
Cellular and molecular targeting for nanotherapeutics in transplantation tolerance. Clin Immunol (2015) 0.76
Pre-transplant sirolimus might improve the outcome of haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide for patients with severe aplastic anemia. Bone Marrow Transplant (2015) 0.76
Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. Blood (2015) 0.75
Induction of Major Histocompatibility Complex-mismatched Mouse Lung Allograft Acceptance With Combined Donor Bone Marrow: Lung Transplant Using a 12-Hour Nonmyeloablative Conditioning Regimen. Transplantation (2016) 0.75
Application of allogeneic bone marrow cells in view of residual alloreactivity: sirolimus but not cyclosporine evolves tolerogenic properties. PLoS One (2015) 0.75
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant (2008) 7.10
The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity (2009) 6.86
Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood (2005) 6.49
The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood (2002) 5.72
Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med (2009) 4.59
Bone marrow transplantation for sickle cell disease. N Engl J Med (1996) 4.02
Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol (2007) 2.61
Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant (2007) 2.61
Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood (2007) 2.36
Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol (1999) 2.26
Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant (2001) 2.10
Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood (2011) 1.90
Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant (2012) 1.89
Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells. Bone Marrow Transplant (2007) 1.79
Cyclophosphamide-induced immunological tolerance: an overview. Immunobiology (1996) 1.72
Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant (1998) 1.57
Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation (2005) 1.51
Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant (2008) 1.45
Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant (2002) 1.38
The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice. Transpl Immunol (2007) 1.35
High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol (2010) 1.33
Low-dose radiation plus rapamycin promotes long-term bone marrow chimerism. Transplantation (2005) 1.32
Induction of chimerism in rhesus macaques through stem cell transplant and costimulation blockade-based immunosuppression. Am J Transplant (2007) 1.30
A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers. J Immunol (1995) 1.28
Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol (2001) 1.17
Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach. J Immunol (1996) 1.14
Drug-induced tolerance to allografts in mice. XII. The relationships between tolerance, chimerism, and graft-versus-host disease. Transplantation (1987) 1.07
Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome. J Immunol (1993) 1.03
Therapeutic efficacy of polyclonal tregs does not require rapamycin in a low-dose irradiation bone marrow transplantation model. Transplantation (2011) 0.88
Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogeneic T-cell-depleted donor marrow. Blood (1994) 0.88
The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation. Haematologica (2012) 0.85
Establishment of stable multilineage hematopoietic chimerism and donor-specific tolerance without irradiation. Transplantation (2000) 0.84
Rapamycin promotes emergence of IL-10-secreting donor lymphocyte infusion-derived T cells without compromising their graft-versus-leukemia reactivity. Transplantation (2007) 0.83
Sirolimus promotes tolerance for donor and recipient antigens after MHC class II disparate bone marrow transplantation in rats. Exp Hematol (2007) 0.81
Cyclosporine and rapamycin act in a synergistic and dose-dependent manner in a model of immunosuppressant-induced kidney damage. Transplant Proc (2005) 0.80
Innate and adaptive immune responses are tolerized in chimeras prepared with nonmyeloablative conditioning. Transplantation (2012) 0.80
Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation. Exp Hematol (2008) 0.79
Considerations in sirolimus use in the early and late post-transplant periods. Expert Opin Drug Saf (2009) 0.79
Extended skin allo- and xenograft survival in mice treated with rapamycin, antilymphocyte serum, and donor-specific bone marrow transfusion. Transplant Proc (1996) 0.77
Superiority of sirolimus (rapamycin) over cyclosporine in augmenting allograft and xenograft survival in mice treated with antilymphocyte serum and donor-specific bone marrow. Transplantation (1997) 0.77
Significant human beta-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating. J Clin Endocrinol Metab (2010) 2.85
Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant (2002) 2.69
Mouse Paneth cell defensins: primary structures and antibacterial activities of numerous cryptdin isoforms. Infect Immun (1994) 1.93
Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution. Neurology (2011) 1.66
Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant (2008) 1.45
Brain atrophy associated with baseline and longitudinal measures of cognition. Neurobiol Aging (2009) 1.31
Prolonged high-level detection of retrovirally marked hematopoietic cells in nonhuman primates after transduction of CD34+ progenitors using clinically feasible methods. Mol Ther (2000) 1.26
Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy. Leukemia (2013) 1.26
Many multipotential gene-marked progenitor or stem cell clones contribute to hematopoiesis in nonhuman primates. Blood (2000) 1.25
Adenosine receptors and cancer. Handb Exp Pharmacol (2009) 1.14
Introduction of a xenogeneic gene via hematopoietic stem cells leads to specific tolerance in a rhesus monkey model. Mol Ther (2000) 1.14
A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1. J Virol (1996) 1.02
Retroviral marking and transplantation of rhesus hematopoietic cells by nonmyeloablative conditioning. Hum Gene Ther (1999) 1.02
Polyclonal B-cell activation reveals antibodies against human immunodeficiency virus type 1 (HIV-1) in HIV-1-seronegative individuals. Proc Natl Acad Sci U S A (1990) 1.01
Immunological and virological studies of natural SIV infection of disease-resistant nonhuman primates. Immunol Lett (1996) 1.01
Clinical and laboratory evidence for a trilineage haematopoietic defect in patients with refractory Diamond-Blackfan anaemia. Br J Haematol (2000) 0.99
Optimal conditions for lentiviral transduction of engrafting human CD34+ cells. Gene Ther (2011) 0.98
Evidence of neurodegeneration in brains of older adults who do not yet fulfill MCI criteria. Neurobiol Aging (2008) 0.97
Relative resistance in the development of T cell anergy in CD4+ T cells from simian immunodeficiency virus disease-resistant sooty mangabeys. J Immunol (2001) 0.96
Characterization of luminal paneth cell alpha-defensins in mouse small intestine. Attenuated antimicrobial activities of peptides with truncated amino termini. J Biol Chem (2000) 0.95
Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplant (2008) 0.92
Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia. Blood (2001) 0.91
Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma. Ann Oncol (2009) 0.90
Persistent low-level engraftment of rhesus peripheral blood progenitor cells transduced with the fanconi anemia C gene after conditioning with low-dose irradiation. Mol Ther (2001) 0.89
Requirements for simian immunodeficiency virus antigen-specific in vitro proliferation of T cells from infected rhesus macaques and sooty mangabeys. AIDS (1990) 0.86
Regulation of IL-2 expression by transcription factor BACH2 in umbilical cord blood CD4+ T cells. Leukemia (2008) 0.84
Sino-orbital-cerebral aspergillosis in immunocompromised pediatric patients. Pediatr Infect Dis J (2000) 0.84
The effects of SCF/G-CSF prestimulation on radiation sensitivity and engraftment in nonmyeloablated murine hosts. Exp Hematol (2001) 0.84
Distinct requirements for C-C chemokine and IL-2 production by naive, previously activated, and anergic T cells. J Immunol (2000) 0.84
Comparison of SIV/SMM replication in CD4+ T cell and monocyte/macrophage cultures from rhesus macaques and sooty mangabeys. J Med Primatol (1990) 0.83
Reduced methyl-CpG protein binding contributing to miR-184 expression in umbilical cord blood CD4+ T-cells. Leukemia (2010) 0.83
Murine bone marrow expressing the neomycin resistance gene has no competitive disadvantage assessed in vivo. Hum Gene Ther (1998) 0.82
A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma. Int J Cancer (2013) 0.82
Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis. Rheumatology (Oxford) (2007) 0.81
Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia. Bone Marrow Transplant (2010) 0.81
Reductions in binding and functions of D2 dopamine receptors in the rat ventral striatum during amphetamine sensitization. Life Sci (1999) 0.80
Successful pregnancy and childbirth after reduced-intensity conditioning and partially HLA-mismatched BMT. Bone Marrow Transplant (2009) 0.80
Analysis of large-volume DNA markers and polymerase chain reaction products by capillary electrophoresis in the presence of electroosmotic flow. J Chromatogr A (2001) 0.80
Transmission of retroviral infection by transfusion of seronegative blood in nonhuman primates. J Infect Dis (1991) 0.80
An anchored restriction-mapping approach applied to the genetic analysis of the Anopheles gambiae malaria vector complex 1. Mol Biol Evol (1995) 0.79
Allogeneic transplantation of multiple umbilical cord blood units in adults: role of pretransplant-mixed lymphocyte reaction to predict host-vs-graft rejection. Leukemia (2008) 0.78
The effect of multidrug-resistance 1 gene versus neo transduction on ex vivo and in vivo expansion of rhesus macaque hematopoietic repopulating cells. Blood (2001) 0.78
No discrepancy between in vivo gene marking efficiency assessed in peripheral blood populations compared with bone marrow progenitors or CD34+ cells. Hum Gene Ther (1999) 0.77
Evidence for simian immunodeficiency virus-specific IgM and IgG response in peripheral blood mononuclear cells of serum enzyme-linked immunosorbent assay-negative nonhuman primates. J Acquir Immune Defic Syndr (1994) 0.76
How much insulin is enough? A quantitative assessment of the transdifferentiaton potential of liver. Diabetologia (2007) 0.75
Expression and localization of hypoxia-inducible factor-1 subunits in the adult rat epididymis. Biol Reprod (2003) 0.75
Addition of rapamycin to anti-CD3 antibody improves long-term glycaemia control in diabetic NOD mice. PLoS One (2013) 0.75
Thermodilution cardiac output values obtained by using a centrally placed introducer sheath and right atrial port of a pulmonary artery catheter. Crit Care Med (1990) 0.75
Treatment of failing glaucoma filtering cystic blebs with tissue plasminogen activator (tPA). J Ocul Pharmacol Ther (1995) 0.75
Presence of SIV antibodies in the sera of infants born to SIV-seronegative monkeys. J Acquir Immune Defic Syndr (1991) 0.75
Acquired haemophilia A after stem cell transplant for sickle cell disease: treatment with recombinant porcine factor VIII (OBI-1) and tolerance induction with rituximab/prednisone. Haemophilia (2014) 0.75
Soft-tipped coronary artery catheters reduce the frequency of coronary artery dissection. Am J Cardiol (1989) 0.75
Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure. Hypertension (2000) 0.75
Effect of ionic strength, pH and polymer concentration on the separation of DNA fragments in the presence of electroosmotic flow. J Chromatogr A (2000) 0.75
Maximization of injection volumes for DNA analysis in capillary electrophoresis. Electrophoresis (2001) 0.75
Arthritis and chest pain in a young black woman. J Tenn Med Assoc (1994) 0.75